SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (1090)3/27/2006 8:03:49 AM
From: quidditch  Read Replies (1) | Respond to of 1255
 
"Under the Agreement, the Company currently receives approximately $2,298,000 per year (subject to the Company providing agreed-upon levels of research)...." Predicate to another shoe to drop??? It's not as if COR can just shrug away even small $$.



To: sim1 who wrote (1090)4/3/2008 1:52:33 AM
From: tuck  Read Replies (1) | Respond to of 1255
 
Rick found this abstract relating to a Servier ampakine:

Message 24463198

I no longer follow Cortex closely and do no know if Cortex might still have an interest in this. If not, it's certainly competition from a former collaborator, unless the compound is actually dead and this is just being published for the resumes of the Servier scientists involved.

Thought I'd throw it out here just in case it was relevant.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News